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Molecular biology of histidine decarboxylase
and prostaglandin receptors
By Atsushi ICHIKAWA,*1,*2,† Yukihiko SUGIMOTO*1,*3 and Satoshi TANAKA*1,*4
(Communicated by Osamu HAYAISHI, M.J.A.)
Abstract: Histamine and prostaglandins (PGs) play a variety of physiological roles as
autacoids, which function in the vicinity of their sources and maintain local homeostasis in the body.
They stimulate target cells by acting on their speciﬁc receptors, which are coupled to trimeric G
proteins. For the precise understanding of the physiological roles of histamine and PGs, it is
necessary to clarify the molecular mechanisms involved in their synthesis as well as their receptor-
mediated responses. We cloned the cDNAs for mouse L-histidine decarboxylase (HDC) and 6 mouse
prostanoid receptors (4 PGE2 receptors, PGF receptor, and PGI receptor). We then characterized
the expression patterns and functions of these genes. Furthermore, we established gene-targeted
mouse strains for HDC and PG receptors to explore the novel pathophysiological roles of histamine
and PGs. We have here summarized our research, which should contribute to progress in the
molecular biology of HDC and PG receptors.
Keywords: histamine, histidine decarboxylase, prostaglandin, prostaglandin receptors, mast
cell, inﬂammation
1. Introduction
In 1968, Tomita et al. discovered by chance that
rats exhibited acute pain reactions (screaming, body
writhing and biting) when they received subcuta-
neous injections of a solution of pyrophosphate
(PPi).1) We extended this observation and further
found that the injection of PPi causes immediate and
temporary increases in local vascular permeability
and subcutaneous histamine content. These PPi-
induced responses were suppressed by a histamine H1
antagonist, diphenhydramine and closely associated
with increasing number of cutaneous mast cells on
the basis of histologic observation, indicating that
PPi-induced inﬂammation was mediated by endoge-
nous histamine from mast cells. We noticed that
increasing PPi-induced vascular responses were
eﬀectively inhibited by simultaneous administration
not only of epinephrine but also of theophylline, both
of which mediate elevation of intracellular cAMP
levels.2) In those days, Lichtenstein and Margolis also
reported similar observation that allergic histamine
release from human leukocytes is inhibited by
catecholamines and methylxanthines, and suggested
a possible regulatory role for cAMP in this process.3)
We then conﬁrmed that PPi induced histamine
release from isolated rat mast cells, which was
inhibited by cAMP analogues and cAMP-elevating
agents such as cathecholamine.4) In addition to these
suppressive eﬀects of cAMP-elevating agents, we
found that PPi-induced inﬂammatory responses were
eﬀectively suppressed by indomethacin and hydro-
cortisone, which inhibit prostaglandin (PG) gener-
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inspired us to focus on the role of PGs in regulation
of PPi-induced inﬂammatory responses. PGE is
abundantly generated and released quickly from
activated macrophages and other leukocytes accu-
mulating in the local inﬂammatory environment. In a
series of studies about the role of PGs in inﬂamma-
tory responses, we found that PGE1 binds to its
speciﬁc membrane receptors with high aﬃnity and
stimulates cAMP accumulation in P-815 cells, a
murine mastocytoma cell line.5) At that time, the
PGE receptor subtypes were pharmacologically
classiﬁed into EP1, EP2, EP3 and EP4 based on
their responses to various speciﬁc agonists and
antagonists, although their molecular identities
remains to be deﬁned. This cell line with high
expression levels of PGE receptors provided us with
an opportunity to explore their molecular identity.
Intheﬁeldofhistamineresearch,awidevarietyof
histamine H1 and H2 receptor antagonists had already
gained success as therapeutic agents for immediate
allergy and peptic ulcer in the 1970s. The mechanism
ofdegranulationofmastcellshadalsobeenintensively
studied by many groups. However, little was known
about the physiological roles of ‘nascent’ histamine,
which was originally regarded as a modulator of tissue
growth,6) and the molecular identity of L-histidine
decarboxylase (HDC), the rate-limiting enzyme for
histamine synthesis, remained to be clariﬁed. At that
time, we noticed that histamine synthesis could be
induced in P-815 cells upon several stimuli and
speculated that de novo synthesized histamine might
have diﬀerent roles from stored histamine.
In the 1980s, a vast majority of studies on
histamine and PGs were performed to achieve the
pharmacological understanding of the receptors using
speciﬁc agonists and antagonists, and the molecular
mechanisms involved in histamine synthesis and PG-
mediated signal transduction remained largely un-
known. During the past twenty years, however, a
wide variety of biotechnological methods became
available in the laboratory such as nucleotide
sequencing, protein sequencing, DNA cloning, poly-
merase chain reaction (PCR), gene expression
systems, gene targeting, immunoblotting, ﬂow cy-
tometry etc. Under such a biotechnology revolution,
we in cooperation with our collaborators carried out
many advanced studies regarding the molecular
biology of HDC and PG receptors. This review
summarizes our studies focusing on the molecular
analyses of HDC and PG receptors and the newly-
identiﬁed physiological roles of histamine and PGs.
2. Regulation of histamine synthesis
Histamine-mediated responses can be classiﬁed
into two categories; one is mediated by stimulus-
dependent release of stored histamine, and the other
is accompanied by induction of histamine synthesis.
HDC plays a crucial role in the latter category, and
hence its identiﬁcation had been anticipated for a
long time. Many groups including us long faced the
tough task in puriﬁcation of the HDC protein, since
the enzymatically active form of HDC was found to
be unstable. Since ﬂuorometric detection of histamine
is sensitive and convenient, it has been used for the
measurement of histamine content. Early studies
demonstrated active histamine synthesis in fetal
liver, pregnant mouse kidney, mastocytoma, and
stomach. In 1984, Watanabe et al. succeeded in
identiﬁcation of histaminergic neuron with an anti-
HDC antibody raised against partially puriﬁed rat
HDC protein, although the molecular identity of
HDC remained unknown.7)
2.1. Puriﬁcation and cDNA cloning of HDC.
We determined the partial amino acid sequence of
HDC for the ﬁrst time through puriﬁcation of the
protein from the mouse mastocytoma cell line P-
815.8) Since histamine synthesis was found to be
drastically induced in these cells upon syngenic BDF
mouse peritoneal cavity incubation, we prepared
crude cell extracts from more than 2,000 mice. Mouse
HDC comprises a homo-dimer, with two identical
53-kDa subunits. We then set out to clone the cDNA
of mouse HDC based on its partial primary sequence.
However, unexpectedly, cDNA cloning of HDC was
achieved through a project which was unrelated to
histamine research: Joseph et al. found a fusion
transcript of putative HDC with the androgen
binding protein, and identiﬁed rat HDC cDNA using
the fusion transcript as a probe.9) In 1990, Joseph
et al. and we reported cDNA cloning of rat and
mouse HDC.9),10) Cloning of HDC cDNA revealed
that HDC is translated as a 74-kDa precursor protein
and might be post-translationally cleaved to a 53–55-
kDa species, which forms a dimer. We further
conﬁrmed that the 53-kDa species is the dominant
form in mouse stomach through puriﬁcation of the
HDC protein.11) Since the carboxyl-terminal (C-
terminal) approximately 20-kDa region of HDC is
unique in the homologous amino acid decarboxylases,
such as dopa decarboxylase, we then focused on the
role of this region and on the post-translational
processing of HDC. Analysis of the recombinant 74-
kDa species expressed in a baculovirus-insect cell
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species is distributed in the insoluble fraction and
exhibits lower enzyme activity in comparison with
the C-terminal deleted 54-kDa species, which is
localized in the cytosol.12),13) In contrast to mouse
HDC, the human recombinant 74-kDa species
exhibited comparable enzyme activity to its C-
terminal deleted 54-kDa species.14) These results
suggested that the C-terminal 20-kDa region of
HDC is involved in regulation of its intracellular
localization and enzymatic activity.
Cloning of HDC cDNA enabled us to determine
the tissue distribution of the transcript. The ex-
pression proﬁle of HDC mRNA was found to largely
coincide with previous reports on the distribution of
the enzymatic activity of HDC, with the exception of
the testis. Although high levels of mRNA expression
were observed in the testis, very little enzyme activity
of HDC was detected. We later revealed using a
speciﬁc antibody raised against HDC that HDC is
expressed in the lineage of male germ cells including
sperm in mice.15) Histamine was found to be released
upon acrosome reaction, indicating that histamine
release might be involved in fertilization. Although
Joseph et al. predicted the presence of a fusion
transcript of HDC and androgen binding protein, no
such transcript was found in the mouse testis. It
remains to be clariﬁed as to why a large amount of
the latent form of HDC is synthesized in male germ
cells. HDC may have special functions in the testis,
which are independent of histamine synthesis.
2.2. Transcriptional regulation of HDC.
Accumulating evidence has indicated that histamine
synthesis is induced in various kinds of cells including
gastric enterochromaﬃn-like cells. Prolonged psycho-
logical stress often results in peptic ulcer, for which
H2 receptor antagonists are used as potent therapeu-
tic drugs, indicating that stress responses lead to
histamine-mediated acid hypersecretion. We hy-
pothesized that the stress-induced glucocorticoid–
ACTH pathway is involved in this increase in
histamine synthesis. Indeed, administration of hydro-
cortisone signiﬁcantly augmented the enzymatical
activity of HDC.16) Dexamethasone, a synthetic
analog of glucocorticoid, potently induced histamine
synthesis in P-815 cells.17) Our ﬁnding that an anti-
inﬂammatory drug, dexamethasone, induced the
synthesis of histamine, which is a potent pro-
inﬂammatory mediator, was interesting and raised
the possibility that histamine is involved not only in
inﬂammatory responses but also in other physiolog-
ical responses. We further demonstrated the positive
eﬀects of dexamethasone on the induction of hista-
mine synthesis in mouse fetal liver cells,18) suggesting
that the activation of glucocorticoid–ACTH pathway
immediately prior to parturition might be involved in
the regulation of fetal hematopoiesis through hista-
mine synthesis. We then focused on the regulation of
gene expression of HDC in P-815 cells. A drastic
induction of HDC was found in the cells treated with a
combination of dexamethasone and phorbol ester, as
well as with a combination of a cAMP analogue and
Ca2D ionophore.19),20) Both studies demonstrated the
stimulus-dependent synergistic induction of HDC,
indicating that histamine synthesis could be induced
upon various combination of stimuli.
Cloning of HDC cDNA enabled us to perform
subsequent genomic cloning and promoter analysis of
the HDC gene. The mouse HDC 5′-ﬂanking region
was found to contain a TATA-like box and a GC
box.21) Ohtsu et al. suggested that down-regulation
of NF-E2 leads to transcriptional activation of the
mouse HDC gene upon peritoneal cavity incubation
in BDF1 mice.22) Wang et al. have continuously
performed promoter analyses of the rat and human
HDC gene.23) They found a series of suppressive
elements inversely involved in gastrin-mediated
induction of HDC. Since few elements that positively
regulate the gene expression of HDC have been
identiﬁed, further analyses are required to reveal the
whole mechanism of gene expression regulation of
HDC.
We determined the structure of the human HDC
gene, which spans approximately 24kb and contains
12 exons, and conﬁrmed that HDC is encoded by a
single copy gene.24) Investigation of the 5′-ﬂanking
region of the human HDC gene suggested that the
c-Myb binding motif is involved in the speciﬁc
expression of HDC in human basophilic leukemia
cells, KU-812-F.25) Kuramasu et al. found that mast
cell- or basophil-speciﬁc expression of human HDC is
regulated by CpG methylation in the promoter
region.26) DNA methylation-mediated regulation
was also found in the cell type-speciﬁc expression of
mouse HDC.27) However, it remains largely unknown
as to how tissue speciﬁc expression of HDC is
regulated. Since transcriptional control of the local
induction of the HDC gene might contribute to
appropriate modulation of histamine-mediated re-
sponses, particularly, in inﬂammatory and immune
responses, the mechanism of HDC gene expression
should be clariﬁed.
2.3. Post-translational regulation of HDC.
Puriﬁcation, cDNA cloning, and comparison with the
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cated that the C-terminal 20-kDa region of HDC is
deleted by post-translational cleavage of the 74-kDa
form. However, it remained unknown how the post-
translational processing of HDC is regulated and
what the physiological roles of the cleavage are. We
succeeded in raising a speciﬁc antibody against the
amino-terminal (N-terminal) region of mouse HDC.
This antibody was found to be useful for immuno-
histochemistry and immunoprecipitation, and has
made a great contribution in the ﬁeld of histamine
research. We investigated the turnover rate of the
nascent HDC protein and clariﬁed its post-transla-
tional processing by immunoprecipitation with this
antibody. In a rat basophilic/mast cell line, RBL-
2H3, we found that the 74-kDa form of de novo
synthesized HDC was very unstable. Further analysis
revealed that the 74-kDa form of HDC was degraded
through the ubiquitin–proteasome pathway.28) In
this cell line, the 74-kDa form was found to be
localized in the cytosol, whereas the 53-kDa form was
in the granule fraction upon sucrose density gradient
fractionation.29) Both fractions contained enzymatic
activity of HDC, indicating that the post-transla-
tional cleavage determines the intracellular local-
ization of HDC, rather than its enzymatic activation,
in this cell line. Granular localization of the 53-kDa
form was also observed in elicited mouse peritoneal
neutrophils.30) Transient expression in COS-7 cells
indicated that recombinant HDC accumulates
mainly in the endoplasmic reticulum (ER).31) How-
ever, since HDC lacks a canonical signal sequence at
its N-terminus, it remained to be clariﬁed as to how
HDC is targeted to the ER. We found that the
nascent 74-kDa HDC protein prepared in in vitro
translation system with rabbit reticulocyte lysate
was post-translationally targeted to exogenously-
added microsomal membranes.31) Since there have
been few reports that demonstrate the post-transla-
tional ER targeting of mammalian proteins, HDC
appears to be targeted to the ER in a unique manner,
the details of which remain unknown.
On the other hand, we also found that proteo-
lytic cleavage of the recombinant 74-kDa protein
results in its enzymatic activation.13) An increase in
histamine synthesis in the stomach under repeated
cold stress was accompanied by induction of proteo-
lytic activity that could cause the post-translational
processing of HDC in vitro. Recently, we identiﬁed
caspase-9 as one of the processing enzymes respon-
sible for enzymatic activation of mouse HDC in P-815
cells.32) Caspase-9-mediated cleavage of HDC was
accompanied by formation of the 53-kDa species and
drastic increases in its enzymatic activity. The
regulation of histamine synthesis through the post-
translational processing of HDC is summarized in
Fig. 1.
2.4. Immune modulation by histamine.
Histamine has a long history as a critical immune
modulator; the histamine H1 receptor (H1R) mediates
the proinﬂammatory eﬀects of histamine, such as
increases in vascular permeability and the expression
of adhesion molecules in endothelial cells, whereas the
H2R is involved in immune suppressive functions.
Since a newly identiﬁed histamine receptor, the H4R,
was found to be expressed speciﬁcally in leukocytes
and to regulate the chemotactic responses of leuko-
cytes, immune modulation by histamine has at-
tracted further attention from researchers.33) Recent
ﬁndings on histamine-mediated immune modulation
are summarized in Fig. 2.
2.4.1. H2R-mediated immune suppression. Hista-
mine is known to be a potent proinﬂammatory
mediator, of which functions are largely mediated
by the H1R. In addition to its H1R-mediated roles,
accumulating evidence suggests that a wide variety of
immune responses are modulated by histamine. A
series of studies have indicated that histamine
suppresses macrophage-mediated inﬂammatory re-
sponses by acting on the H2R. We focused on the role
of the H2R in suppression of tumor immunity, since
clinical trials indicated that several H2R antagonists,
in particular cimetidine, has suppressive eﬀects on
tumor development. We demonstrated that local
histamine synthesis in tumor tissues suppresses the
local expression of cytokines, such as IFN-., TNF-,,
and lymphotoxin-O, by acting on the H2R.34),35)
Although it remains unknown as to what kinds of
cells produce histamine in tumor tissues, tumor-
inﬁltrating macrophages and neutrophils are poten-
tial candidates for the source of histamine. Establish-
ment of gene targeted mouse strains for the H1Ra n d
H2R clariﬁed the critical roles of histamine in helper
T responses; the H1R is involved in augmentation of
Th1 responses, whereas the H2R is involved in the
suppression of both Th1 and Th2 responses.36)
2.4.2. IgE-mediated induction of histamine synthesis.
Histamine synthesis in mast cells is not always static
but occasionally inducible. A wide variety of stimuli
can augment histamine synthesis in mast cells, such
as IL-3, stem cell factor, butyrate, phorbol ester,
and glucocorticoid. We noticed that the amount of
intracellular histamine is increased during sensitiza-
tion of mast cells with IgE. In 2001, two groups
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3-dependent bone marrow-derived mast cells
(BMMCs) in the absence of its speciﬁc antigen. We
demonstrated that a drastic increase in histamine
synthesis occurs in murine BMMCs sensitized with
IgE.37) Transcriptional activation of the HDC gene
was induced by IgE in the absence of its antigen.
Accumulating evidence indicated that the potency of
IgE varied according to the clone, although this
response was found to occur in the absence of its
antigen. Potent IgE clones were found to induce
cytokine production, such as IL-3, IL-4 and IL-6,
histamine synthesis, migration, and adhesion. Induc-
tion of HDC in BMMCs was also observed upon IgE-
mediated antigen stimulation or treatment with
reagents that mobilize intracellular Ca2D concentra-
tions, such as thapsigargin and A23187.37),38) We
demonstrated that the Ca2D inﬂux induced by IgE
alone was mediated by pharmacologically diﬀerent
channels from that activated upon antigen stimula-
tion.38) Absence of protein kinase C (PKC) OII did
not aﬀect Ca2D mobilization upon antigen stimula-
tion but abolished the Ca2D mobilization induced by
IgE alone, indicating the critical role of PKCOII in
the IgE-mediated increase in histamine synthesis.39)
Since hyper IgE syndrome has often been observed in
chronic allergy diseases, such as hay fever and atopic
dermatitis, and lowering of serum IgE levels with an
anti-IgE antibody ameliorates disease severity, anti-
gen-independent eﬀects of IgE on mast cells might be
involved in exacerbation of such chronic diseases.
2.5. Gene targeting of HDC. Identiﬁcation of
the HDC gene provided us with the opportunity to
establish gene-targeted mice. An international col-
laboration was carried out to prepare the HDC!/!
mouse strain among three countries, Japan, Canada,
and Hungary, including our group. Unexpectedly,
HDC!/! mice were fertile and exhibited no gross
Fig. 1. Regulation of histamine synthesis by the post-translational processing of mouse HDC. HDC is initially translated as the precursor
form, with a molecular weight of 74-kDa (74-kDa HDC). Since HDC lacks the canonical signal sequence at its N-terminus, HDC
appears to be post-translationally targeted to the ER in an unidentiﬁed manner. One of the processing enzymes that are responsible
for the post-translational processing of HDC was found to be caspase-9. The 53-kDa form of HDC is localized mainly in the granule
fraction and possesses higher enzymatic activity. On the other hand, the 74-kDa form of HDC undergoes degradation through the
ubiquitin–proteasome pathway. Histamine is synthesized in the cytosol and transported into the granules by vesicular monoamine
transporter-2 (VMAT2). Stored histamine is released from the granules upon various stimuli, such as IgE-mediated antigen
stimulation in mast cells. Excess amounts of histamine might be exported through organic cation transporter-3 (OCT3), which is
known to be a transporter for organic cations with low aﬃnity but high capacity. The 74-kDa HDC is the dominant form in the cells
lacking histamine granules, such as macrophages, whereas the 53-kDa HDC is detected in the granule-containing cells, such as mast
cells and neutrophils.
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was observed in the tissue homogenates of HDC!/!
mice, indicating that HDC is the sole enzyme for
histamine synthesis. Although tissue histamine levels
were also drastically decreased in the HDC!/! mice,
trace amounts of histamine were detectable in their
tissues. Since enteric bacteria, such as lactobacillus,
express the HDC ortholog and produce histamine, it
was diﬃcult to eliminate such trace amounts of
residual histamine from HDC!/! mice. However,
histamine content in the tissues of HDC!/! mice was
controllable through dietary supplementation of
histamine.41),42) We found that dietary histamine
accumulated in the spleen of HDC!/! mice and that
macrophages were responsible for this uptake.42)
It was anticipated that IgE-dependent immedi-
ate allergic responses were abolished in HDC!/!
mice.41),43) However, we could not conclude that the
resistance to anaphylactic reaction was due solely to
the lack of histamine in these mice, since their tissue
mast cells exhibited abnormal granule morphology
and hence may have functional defects.40) Aberrant
granule formation in HDC!/! mice suggested that
histamine might aﬀect mast cell maturation, but the
functional roles of the histamine receptors in mast
cells remains largely unknown. Although HDC!/!
mice are a useful model for studying allergy and
inﬂammation, it is critical to speciﬁcally characterize
tissue mast cells that lack HDC.
Histamine is one of the critical acid secreta-
gogues in the stomach. We then investigated gastric
acid secretion in HDC!/! mice.44) HDC!/! mice were
found to be sensitive to exogenous histamine but
were resistant to gastrin, which induces gastric acid
secretion. Our study revealed the roles of histamine
in gastric acid secretion induced by muscarinic
stimulation and gastrin (Fig. 3). HDC!/! mice
exhibited similar features to mice continuously
Fig. 2. Immune modulation by histamine produced by various leukocytes. The actions of histamine can be classiﬁed into two categories;
one mediated by stored histamine and the other by nascent histamine. In the former cases, histamine is produced and stored in the
granules of mast cells and basophils and is liberated upon stimulation. In the latter case, HDC is induced at the transcriptional level
upon various stimuli, and de novo synthesized histamine modulates the immune responses. Since several functions of histamine have
been proposed through the experiments with exogenously-added histamine, the origin of histamine involved in such responses remains
to be determined. Recent topics in this ﬁeld are the identiﬁcation of the H4R, which is expressed mainly in leukocytes, such as mast
cells, eosinophils, and T cells.
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nemia and acid hypersecretion in response to
histamine. Although H2R!/! mice shared many
features with HDC!/! mice, such as hypergastrine-
mia, a marked hypertrophy with enlarged folds of the
gastric mucosa was observed only in the H2R!/!
mice.45) These results suggested that histamine is
involved in the maintenance of gastric mucosal
cellular composition.
Accumulating evidence suggests that the
HDC!/! strain is a useful tool in identiﬁcation of
novel physiological roles of histamine.46),47) The
combinatorial use of gene targeted mice for HDC
and histamine receptors should lead to great ad-
vancements in histamine research.
3. Biochemical and molecular characterization
of prostaglandin (PG) receptors
Biochemical studies showed that the actions of
PGs are mediated by G proteins, and ligand binding
properties indicated that a variety of PGs cross-react
with the other receptors, suggesting structural
similarity of the receptors. It was repeatedly reported
that PG actions are associated with changes in
second messengers. Some PG actions were found to
be associated with changes in cyclic AMP (cAMP)
levels, phosphatidylinositol (PI) turnover or free
calcium ion concentrations in the cell. However, none
of the receptors had been isolated and cloned until
the thromboxane (TX) A2 receptor was puriﬁed from
human blood platelets and its cDNA cloned by
Narumiya et al.48) This study revealed that the TXA2
receptor was a G-protein-coupled, rhodopsin-type
receptor with seven transmembrane domains.
3.1. Cloning and expression of PG receptors.
In collaboration with Dr. Narumiya, we employed
a homology screening strategy using mouse P-815,
lung, kidney, and ovary cDNA libraries, and sub-
sequently identiﬁed the structures of four subtypes
of PGE receptors,49)–52) the PGI2 receptor,53) and
PGF2, receptor.54) These receptors were expressed
and their ligand binding properties and signal trans-
duction were examined in homogenous populations in
heterologous expression systems (reviewed in Refs.
55, 56). In the following section, we summarize the
structure and biochemical properties of the PGE
receptor subtypes.
3.1.1. PGE receptor subtypes. We isolated func-
tional cDNAs of the mouse PGE receptor subtypes,
EP1, EP2, EP3 and EP4, and characterized their
structural and biochemical properties using recombi-
nant receptors expressed in mammalian cells.49)–52)
EP1, EP2, EP3 and EP4 receptors consist of 405,
362, 365, and 513 amino acid residues with seven
hydrophobic segments corresponding to putative
transmembrane domains, respectively. The binding
properties of the four PGE receptors were examined
in detail with various synthetic PGE analogues, and
found to be in good agreement with the results from
the pharmacological experiments. For example, the
cloned EP1 receptor shows about ten times higher
aﬃnity to PGE2 and iloprost than PGE1, while the
other three receptors bind to PGE2 and PGE1 with
equal aﬃnities and to iloprost with much lower
aﬃnity. 17-Phenyl-PGE2 shows the highest aﬃnity
to EP1, while butaprost and M&B28767 are the best
ligands to EP2 and EP3, respectively. Although
AH23848B was used as a selective antagonist for
Fig. 3. Roles of histamine in gastric acid secretion. Histamine, acetylcholine (muscarinic), and gastrin are major secretagogues in gastric
acid secretion. Accumulating evidence suggests that acetylcholine and gastrin stimulate histamine release from ECL cells, which
synergistically enhance the acid secretion through direct stimulation of parietal cells by these secretagogues. Massive and prolonged
acid secretion by gastrin was found to require transcriptional activation of the HDC gene. Investigation using the HDC!/! mice
revealed that histamine plays a critical role in gastrin-mediated acid secretion but not in muscarinic acid secretion.
A. ICHIKAWA,Y .S UGIMOTO and S. TANAKA [Vol. 86, 854EP4, this ligand showed moderate binding aﬃnity for
EP4. Signal transduction analyses demonstrated that
these receptor subtypes couple to diﬀerent pathways,
as suggested by various biochemical studies: EP1
elicits the elevation of intracellular [Ca2D], EP2 and
EP4 stimulates adenylate cyclase while EP3 inhibits
the enzyme.
The EP1 receptor mediates the PGE2-induced
elevation of free Ca2D concentrations in CHO cells.
This increase is dependent on extracellular Ca2D and
occurs without a detectable PI response, suggesting
that EP1 regulates Ca2D channel gating via an
unidentiﬁed G protein.57) It was reported that EP1
expressed in Xenopus oocytes can couple to TRP5, a
candidate for the receptor-activated Ca2D channel
(RACC), and this coupling is inhibited by an anti-
sense oligonucleotide for Gq/G11 but not by one for
Gi1 (Fig. 4).58) The EP2 and EP4 receptors couple to
Gs and mediate increases in cAMP concentrations.
The major signaling pathway of the EP3 receptor is
inhibition of adenylate cyclase via Gi. It should be
noted, however, that EP3 receptors do not couple
exclusively to the pathways described but often to
more than one G protein and signal transduction
pathway. Hatae and Yamaoka found that when
expressed in COS7 cells, the EP3 receptor elicits
augmentation of EP2- or EP4-induced cAMP for-
mation via Gq/11.59),60) Interestingly, this EP3-in-
duced superactivation is observed irrespective of the
C-terminal tail structure; EP3,, O, ., which are the
C-terminal splicing variants, and C-terminal-trun-
cated mutant EP3 showed similar responses. Such
coupling of EP3 to Gq/11 is dependent on lipid-raft
structure. Localization of EP receptors to lipid raft
microdomains may determine the cell-speciﬁc signal
transduction pathway of EP3. In contrast, of interest
is the presence of two EPs, EP2 and EP4, that are
coupled to increases in cAMP. Nishigaki et al. found
that EP4 shows higher sensitivity to agonist-induced
desensitization than EP2.61) However, EP2 and EP4
apparently function redundantly in some processes.
For example, both EP2 and EP4 mediate potentia-
tion of Th17 expansion through cAMP–PKA signal-
ing by PGE2, although the extent of the contribution
by each receptor may be diﬀerent.62) On the other
hand, there are processes in which EP2 and EP4 play
distinct roles. Some of these may be due to selective
expression of either receptor in relevant cells such
as the action of EP2 during cumulus expansion in
ovulation and fertilization, and that of EP4 in closure
of the ductus arteriosus (see 3.4.1).63),64) However,
only EP4 stimulates IL-23 production from dendritic
cells in mice, although both EP2 and EP4 are
expressed in these cells.62) In 2003, Fujino et al.
found that EP4 couples to PI3-kinase in addition to
activation of adenylate cyclase.65) Later, Buchanan
et al. demonstrated that EP4 activates PI3-K
through activation of O-arrestin/Src pathway.66)
Furthermore, we found that both EP2 and EP4
couple to PI3-kinase in naive T cells.62) Indeed, Chun
et al. demonstrated that EP2 is also coupled to PI3-
kinase via O-arrestin1 (Fig. 4).67)
3.2. Identiﬁcation and characterization of
PG receptor isoforms. In addition to the receptor
subtypes encoded by diﬀerent genes, alternative
splicing can create several isoforms of the EP3
receptor, which diﬀer in their C-terminal sequence.
There exist three isoforms in mouse,68),69) four iso-
Fig. 4. Signal transduction pathways of the four PGE receptor subtypes. EP1 is coupled to Gq/11 (Gq) and intracellular Ca2D
mobilization. EP2 and EP4 are coupled to the Gs/adenylyl cyclase/cAMP/protein kinase A (PKA) pathway. Recently, it was shown
that the two receptors are also coupled to the O-arrestin (OArr)/Phosphoinositide 3-kinase (PI3-K) pathway. The EP3 receptor is
mainly coupled to Gi, but in particular cell types, EP3 augments EP2/EP4-induced cAMP formation via the Gq/phospholipase C/
Ca2D pathway.
Molecular biology of HDC and PG receptors No. 8] 855forms in bovine,70) and six isoforms in human
(Fig. 5A).71) These isoforms displayed identical ago-
nist binding properties, but were functionally diﬀer-
ent in their eﬃciency of G protein activation,
speciﬁcity of G protein coupling, sensitivity to
agonist-induced desensitization and leakage of ago-
nist-insensitive constitutive activity.72),73) For exam-
ple, mouse EP3, and EP3O both couple to Gi, but
three orders lower concentration of agonists were
required for EP3, than EP3O for activation of G
protein. EP3, undergoes both short and long term
agonist-induced desensitization, whereas EP3O
undergoes neither short nor long term desensitization.
On the other hand, bovine EP3A couples to Gi to
induce the inhibition of adenylate cyclase, EP3B and
C couple to Gs to increase cAMP, and EP3D couples
to Gq, in addition to Gi and Gs, to evoke a pertussis
toxin-insensitive PI response. RT-PCR analyses
demonstrated that these mRNAs are expressed in
various tissues in diﬀerent relative amounts. In order
to elucidate the role of the C-terminal domains of the
EP3 isoforms, we constructed a mutant EP3 receptor
in which the C-terminus was truncated at the splice
site. The mutant receptor retained the ability to
associate with Gi2, and its binding aﬃnity showed
sensitivity to guanine nucleotides. However, expres-
sion of the mutant receptor alone without agonist
stimulation was enough to inhibit adenylate cyclase
(Fig. 5B). Pertussis toxin treatment of cells express-
ing this mutant receptor raised forskolin-induced
cAMP accumulation. These results indicate that the
C-terminal domain of the EP3 receptor plays a role in
preventing the leakage of agonist-independent con-
stitutive activation of G proteins.
Fig. 5. Structure and constitutive activity of mouse EP3 receptor isoforms (EP3,/O/.) and the C-terminus-truncated mutant receptor
(T335). A. Sequences of the C-terminal domains created by alternative splicing are shown. T335 is a C-terminus-truncated mutant
receptor. B. Diﬀerent agonist-induced and constitutive Gi activity in mouse EP3 receptor isoforms (EP3,/O/.) and the C-terminus-
truncated mutant receptor (T335).
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of PG receptors. PG receptors have been suggested
to exist in many tissues in the body, based on
previous pharmacological and biochemical studies.
The various therapeutic eﬀects as well as side-eﬀects
of aspirin-like drugs also reﬂect their involvement in
various physiological and pathophysiological proc-
esses. The exact distribution of each receptor and the
identities of cells expressing each receptor, however,
remain mostly unknown because of the relatively low
expression levels of these receptors and the expression
of multiple receptors in a single tissue. We ap-
proached this issue using molecular biological tech-
niques such as Northern blot analysis and in situ
hybridization, which provided detailed information
on PG receptor distribution.74) These analyses have
shown that each receptor is speciﬁcally distributed in
the body, and that expression levels are variable
among tissues.
3.3.1. Kidney. Among the four PGE receptors,
EP3 and EP4 receptors are widely distributed
throughout the body, with their mRNAs being
expressed in almost all mouse tissues examined. In
contrast, the distribution of EP1 mRNA is restricted
to several organs such as the kidney, lung and
stomach, and EP2 is the least abundant among the
EP receptors. In general, the PGE receptor subtypes
show ‘distinct’ cellular localizations. For example, in
the kidney, we found that EP3 receptor is expressed
in the tubular epithelium of the outer medulla,
especially in the thick ascending limb and cortical
collecting ducts, EP1 receptor in the papillary
collecting ducts and EP4 receptor in the glomerulus
(Fig. 6A).75) The distribution pattern appears to
correspond with the PGE2-mediated regulation of ion
transport, water reabsorption and glomerular ﬁltra-
tion, respectively. However, there was no expression
of EP2 mRNA.
3.3.2. Nervous system. The diﬀerential expression
of PGE receptors also occurs in the central nervous
system. EP3 mRNA is widely expressed in the
neurons of the cortex, hippocampus, thalamus,
Fig. 6. Regulation of PGE receptor gene expressions. A. Constitutive expression of PGE receptor genes in diﬀerent cell types of kidney.
Schematic representation of the distribution of PGE receptors in the nephron (center panel). EP1 is expressed in the collecting duct
(blue), EP3 is expressed in thick ascending limb (yellow), and EP4 is expressed in the glomerulus (red). EP1 and EP3 are involved in
inhibition of water and ion transport, respectively. EP4 is involved in regulation of glomerular ﬁltration rate. B. Inducible gene
expression of COX-2 and the EP2 receptor in cumulus cells (hormonal stimuli) or macrophage (proinﬂammatory stimuli). In these
cells, gene expression of COX-2 and EP2 is induced in a similar manner. As a result, COX-2-derived PGE2 acts on the EP2 receptor,
and elicits functional changes via the Gs/cAMP/PKA pathway in an autocrine fashion.
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Among these subregions, in the hypothalamus, EP3
mRNA is expressed in the neurons in the medial and
median preoptic nuclei, especially in neurons sur-
rounding the organum vasculosa lamina terminalis
(OVLT). The OVLT has been regarded as a key
structure with a poor blood-brain-barrier. Indeed,
cyclooxygenase-2 (COX-2) is induced in this region in
response to the peripheral administration of lipo-
polysaccharide (LPS). The EP3 receptor in this
region may be involved in fever generation (see
3.4.2). In contrast, expression of EP4 and EP2
mRNA was reported in small groups of neuronal
and non-neuronal cells.77) Zhang and Rivest further
found that expression levels in some of these cells
were increased upon the peripheral administration of
LPS, which is an interesting ﬁnding in respect to the
regulation of receptor gene expression by inﬂamma-
tory stimuli (see 3.3.3). On the other hand, EP1, EP3
and EP4 mRNAs are expressed in neurons of
the dorsal root ganglion (DRG).78) EP3 mRNA is
expressed in half of the DRG neurons and these are in
general small in size, suggesting the involvement
of this receptor in PGE2-mediated hyperalgesia.
However, pain modulation by PGs is also closely
associated with IP expression in DRG neurons.78)
3.3.3. Transcriptional regulation of EP receptor gene
expression. COX-2 gene expression is known to be
induced upon hormonal and proinﬂammatory stimuli.
Such gene induction by hormonal and proinﬂamma-
tory signals is also observed for the EP2 receptor
(Fig. 6B). For example, macrophages produce large
amounts of PGE2 in response to LPS treatment, and
the resultant PGE2 at least in part act on the macro-
phages themselves, resulting in inhibition of cytokine
release. This inhibitory eﬀect of PGE2 is exerted
through production of cAMP, suggesting the involve-
ment of EP2 and/or EP4 receptors. We examined the
details of expression of EP2 and EP4 receptors in
macrophage cells, J774.1, and found that the former
is eﬀectively induced in response to LPS treatment in
a time course similar to that of COX-2.79) We further
demonstrated that the up-regulation of EP2 by LPS
is completely inhibited by the simultaneous admin-
istration of interferon-.. Induction of the EP2
receptor gene was also found in mouse peritoneal
resident macrophages upon their exposure to LPS.80)
In contrast, abundant expression of EP4 mRNA is
present before the addition of LPS in these macro-
phages. Thus, EP2 may serve as an inducible type of
PGE receptor in macrophages, being regulated in a
manner similar to that proposed for COX-2.
Hormonal stimuli can change both localization
and expression level of PGE receptor subtypes. We
found that the abundance and localization of mRNAs
for EP2, EP3 and EP4 change considerably when
mice undergo pseudopregnancy by treatment with
PMSG and hCG.81) EP2 mRNA, which is hardly
detectable before stimulation, is expressed consider-
ably in luminal epithelial cells. This expression peaks
on day 5 of pregnancy and disappears quickly
thereafter. Because this induction occurs in parallel
with that of COX-2 in this tissue, is coincident with
the time of blastocyst implantation, and is sensitive
to indomethacin treatment, EP2 may be involved in
the implantation process. EP4 mRNA expression
sharply increases on day 3 of pseudopregnancy and is
maintained at a high level after day 5. In addition,
EP2 expression is limited to luminal epithelial cells
on day 0 but is further found in endometrial stromal
cells and the glandular epithelium after induction. In
contrast to these receptors expressed in the endome-
trium, EP3 receptor mRNA is expressed in smooth
muscle layers. Its expression level is low on day 1,
increases up to day 5 and then declines. The cellular
localization of EP4 mRNA changes during pseudo-
pregnancy; it is expressed in the longitudinal muscle
layer before stimulation, but in circular smooth
muscles on day 5. Thus, analysis of the uterine
expression of EP receptors provides an interesting
example of PG receptor induction under physiolog-
ical conditions. It should be noted that gonadotropins
also induce EP2 mRNA as well as COX-2 with a
similar time course in the ovary (see 3.4.1). 63),82)
Since EP2 mRNA is expressed in luminal
epithelial cells of the uterus, we hypothesized that
the mouse EP2 gene may be regulated by the
progesterone receptor (PR). In order to test this
possibility, we investigated the transcriptional regu-
lation of EP2 gene expression by reporter gene
analysis using HeLa cells with or without expression
of the PR.83) The 5′-ﬂanking region (!3260 to !27,
upstream of the translation initiation site) exhibited
progesterone-induced promoter activation and basal
promoter activity in the presence of PR. Using
successive deletion analysis, we determined the six
regulatory regions in the EP2 gene. Three regions
were found to be involved in progesterone-induced
promoter activation, whereas the other three regions
were involved in basal promoter activity in the
presence of PR. We identiﬁed a novel PR-binding
sequence, 5′-G(G/A)CCGGA-3′, in two basal pro-
moter regions and Sp1- and Sp3-binding sites in the
other basal promoter region. Thus, we ﬁnally
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be involved in regulation of the basal promoter
activity of the EP2 gene.
3.4. Physiological roles of PG receptor sig-
naling. PGs are presumed to play many important
roles in a variety of physiological and pathophysio-
logical processes in the body. These roles of PGs
have been suggested both by examining the eﬀects of
aspirin-like drugs which inhibit PG production and
by analyzing the in vitro and in vivo actions of each
PG added exogenously. However, it is not necessarily
clear as to which type of PG and which type of PG
receptor are involved in each process. Neither is it
clear as to how critical the action of PGs is in each
process. In order to approach this issue, we employed
targeted disruption of the PG receptor gene and
generated EP1-, EP2-, EP3-, EP4-, and FP-deﬁcient
mice.63),64),84),85) Since recent progress on the roles of
PG receptors in physiological and pathological
conditions has been described elsewhere,86),87) in this
review, we focused on the roles of EP2 signaling in
fertilization as one of the representative physiological
actions of PGs and the roles of EP3 signaling in
fever generation as one of the pathological actions of
PGs.
3.4.1. Impaired ovulation and fertilization in EP2-
knockout mice. E- and F-type PGs are implicated in
many aspects of reproductive functions. These
include not only peripheral reproductive processes
but also gonadotropin secretion in the central
nervous system. To date, it has been accepted that
luteinizing hormone-releasing hormone (LHRH) is
secreted by the hypothalamus in response to PGE2.
Although it was revealed that estradiol treatment is
followed by increased expression of EP1 and EP3
mRNAs in LHRH neurons, no apparent changes were
found in serum concentrations of LH and FSH in
female mice of the COX-1- and COX-2-knockouts.88)
In the ovary, the PG content of follicles increases as
the follicles mature. Indomethacin abolishes LH-
induced ovulation, and this eﬀect is reversed by
treatment with PGE2 or PGF2,.89) Studies on mice
deﬁcient in COX-2, but not COX-1, showed multiple
reproductive failures in early pregnancy, such as
ovulation, fertilization, implantation, and deciduali-
zation, suggesting that PGs play essential roles in
these processes.90) Since IP-, EP1-, EP3-, EP4-, and
TP-deﬁcient females are fertile, these receptors may
be dispensable in female reproduction. Likewise,
ovulation, fertilization and implantation are normal
in mice lacking the FP receptor gene, suggesting that
PGF2, is not crucial for these processes.84) We
reported a failure in early pregnancy in EP2-deﬁcient
female mice.63) We found that EP2-deﬁcient female
mice consistently deliver fewer pups than their wild-
type counterparts irrespective of the genotypes of the
mating males. We detected slightly impaired ovula-
tion and dramatic reduction in fertilization in EP2-
deﬁcient mice and concluded that failure in early
pregnancy in COX-2-deﬁcient mice is at least in part
due to dysfunction of the EP2 receptor. We further
found that this phenotype is due to impaired
expansion of the cumulus oophorus. To obtain
insight into the mechanism causing fertilization
failure in the EP2-deﬁcient cumulus, we compared
the gene expression proﬁles of wild-type and EP2-null
cumuli isolated from the oviduct ampulla.91),92) We
found increased gene expression of chemokines
such as ccl2, ccl7 and ccl9 in EP2-deﬁcient cumuli
compared with those of wild-type. Furthermore, we
molecularly dissected the functional consequences of
enhanced chemokine signaling in EP2-mutated cu-
muli, and found that chemokine signaling facilitates
both sperm attraction to the cumulus and compac-
tion of the cumulus by integrin-mediated extracel-
lular matrix assembly, the latter of which is down-
regulated by PGE2-EP2 signaling to allow sperm
penetration for successful fertilization (Fig. 7).
3.4.2. Lack of fever generation in EP3-knockout mice.
Fever is one of the most well-known phenotypes in
which endogenous PGs play roles, because of the
powerful anti-pyrogenic eﬀects of aspirin-like drugs.
A fever is elicited by cellular components of infectious
organisms, such as LPS, as well as by non-infectious
inﬂammatory insults. Both exogenous pyrogens and
non-infectious insults stimulate the production of
cytokines that work as endogenous pyrogens. These
cytokines, IL-1 and IL-6 act on the preoptic area
(POA), which then stimulates the neural pathways
that raise body temperature. PGE2 has been sug-
gested to work as a central mediator of fever93);E -
type PG is a powerful inducer of fever when injected
into the brain, and the level of PGE2 increases in the
POA during LPS-induced fever, and indomethacin
completely abolishes both LPS-induced fever and
increased levels of PGE2 in the POA.94) On the other
hand, Mitchell et al. argued against the role of
PGE,95) based on the ﬁndings that some PGE
antagonists failed to suppress cytokine-induced fever,
and that aspirin-like drugs failed to inhibit macro-
phage inﬂammatory protein-1 (MIP-1)-induced and
IL-8-induced fever. We used mice lacking each
subtype of PGE receptor to address the above
issues.85) In this study, mice lacking each of the four
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EP4 receptor, were generated by homologous recom-
bination, and the fever responses to PGE2, IL-1O or
LPS were examined. We found that only the EP3
receptor-deﬁcient mice fail to show a febrile response
to all of these stimuli. This study thus clearly
demonstrated that PGE2 mediates fever generation
in response to both exogenous and endogenous
pyrogens by acting on the EP3 receptor (Fig. 8).
Receptor-activator of NF-5B ligand (RANKL)
and its receptor RANK are essential regulators of
bone remodeling, lymph node organogenesis and
formation of a lactating mammary gland.96) Just
recently, Penninger and colleague found the
RANKL/RANK signaling in the septal to POA
region plays a critical role in LPS-induced or
cytokine-induced fever generation.97) Central admin-
istration of recombinant RANKL results in fever
generation, which is alleviated by astrocyte-speciﬁc
gene disruption of RANK. Peripheral administration
of LPS or IL-1O augments RANKL/RANK expres-
sion in the septal/POA region. Intriguingly, RANKL
injection induces COX-2 expression and PGE2
accumulation in the septal/POA region, and
RANKL-induced fever generation was abolished by
COX-2 inhibitor or gene disruption of EP3 receptor.
These results indicate that RANKL/RANK signaling
in the astrocyte of septal/POA region mediates the
febrile response via induction of the COX-2/PGE2/
EP3 receptor system (Fig. 8).
Which type of cell expressing EP3 receptor is the
most critical for PGE2-induced fever generation? In
our primary analysis,76) we found that the mRNA for
the EP3 receptor is particularly abundant in the
POA region. We further conﬁrmed that the rat EP3
receptor protein is expressed in the cell bodies of
these neurons with a distribution pattern similar to
that of EP3 mRNA.98) Recent report by Lazarus
et al. demonstrated that POA-speciﬁc EP3 gene
disruption is enough to abolish PGE2-induced fever
generation.99) Thus, the EP3 receptor expressed in
neurons in the POA region works as an initial input
of ‘pyrogenic’ PGE2 to alter the set point of thermal
regulation.
Then, what occurs after EP3 activation in these
neurons? Nakamura et al. revealed that most EP3-
positive neurons in the POA (86%) are also positive
for glutamate decarboxylase (GAD) 67 (gad67) gene
expression and that injection of the GABAA agonist
muscimol injection into the raphe pallidus nucleus
blocks PGE2-induced fever.100) Based on these
results, they proposed the mechanism of PGE2-
induced fever as follows: the EP3-expressing neurons
are GABAergic and exert tonic inhibition on raphe
pallidus neurons which couples to stimulation of
sympathetic nerves in the steady state (in the
absence of PGE2), and when cytokine signals
stimulate PG production within the POA, PGE2
somehow inhibits the GABAergic activity of EP3-
expressing neurons, allowing the excitation of raphe
Fig. 7. Schematic model of the roles of PGE2–EP2 signaling in cumulus ECM status and successful fertilization. Gonadotropins
stimulate secretion of extracellular matrix (ECM) components such as hyaluronan from cumulus cells. Ovulation-associated signals
induce the gene expression and production of chemokines such as CCL7 in cumulus cells. CCL7 stimulates cumulus ECM protein
assembly to protect the oocyte in an autocrine manner, and facilitates sperm migration to cumulus–oocyte complexes. Once the
complexes reach the fertilization site, PGE2/EP2/cAMP signaling down-regulates such chemokine actions on the cumuli so that
chemokine signaling does not interfere with sperm penetration.
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found that particular subtypes of GABAA receptors
and EP3 are co-expressed in the POA neurons, in
which GABAA expression levels are altered in a fever-
associated manner upon PGE2 administration.101)
These results suggest that the EP3-expressing POA
neurons are also susceptible to negative regulation by
GABA. Indeed, local application of muscimol into
the POA has been shown to induce hyperthermia in
an NSAID-insensitive manner.102),103) This eﬀect of
muscimol may reﬂect the existence of a more
universal thermal regulation mechanism by GABA
within the POA. If this is true, PGE2–EP3 signaling
may stimulate the susceptibility to GABA inhibition
by aﬀecting the GABAA channel properties such as
sensitivity to GABA or GABA-elicited responses of
the POA neurons (Fig. 8).
4. Perspective
Accumulating evidence indicates that nascent
histamine plays critical roles in a wide variety of
pathophysiological responses, which are regulated
solely by HDC. Recently, histamine H3 and H4
receptors were identiﬁed and cloned, arousing con-
siderable interest in the unknown functions of
histamine in the central nervous and immune
systems.104),105) It is increasingly recognized that
where and when histamine is synthesized are the
critical issues for better understanding of histamine-
mediated responses. On the other hand, the mecha-
nisms whereby PGE2 exerts its multipotent actions,
once a mystery in physiology, have been clariﬁed
through the biochemical identiﬁcation and cDNA
cloning of the four EP subtype receptors. Further-
more, development of highly selective agonists and
antagonists to each EP subtype and information
obtained by studies on mice deﬁcient in each EP
receptor now provide opportunities to apply our
knowledge to manipulate various PGE2-mediated
pathological processes.106)
Our ﬁndings have revealed a comprehensive
picture of the physiological roles of histamine and
PGs by providing the missing pieces in their research
ﬁelds. Comparison and combined use of gene-targeted
mice for its synthesizing enzyme and its speciﬁc
receptor have provided important insights into the
role of histamine and PGs, respectively. Communi-
cation between diﬀerent cells through ligand-receptor
interactions is one of the fundamental components
required for maintaining homeostasis in the local
environment. The spatiotemporal regulation of ligand
synthesis and receptor expression determines the
impact of histamine and PGs. Co-ordinate progress
in research on both the ligand and receptor is required
for better understanding of the functions of autacoids.
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Fig. 8. Mechanism of inﬂammatory fever. Peripheral stimuli
such as endotoxins initiate macrophage to produce IL-1O, which
somehow induces RANKL expression in septal/POA region.
RANKL, by acting on RANK on the astrocytes, initiates COX-2
expression and PGE2 production. PGE2 modiﬁes the GABAA
subunit composition via EP3-Gi/o pathway, and such a rapid
modulation of GABAA channel may inhibit the GABAergic
activity of EP3-expressing neurons, allowing the excitation of
raphe (rRPa) neurons, leading to sympathetic nerve-mediated
thermogenesis.
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